Figure 1.

Study design. HC, hydroxycarbamide. *All patients received low‐dose aspirin unless contraindicated. ^†Patients randomized to HC plus placebo were eligible to cross over after Week 16 to receive open‐label ruxolitinib if safety criteria were met. ^‡The primary endpoint was the proportion of patients who achieved ≥50% improvement in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score cytokine symptom cluster at Week 16.